DR
Therapeutic Areas
Siolta Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| STMC-103H | Prevention of Atopic Dermatitis in high-risk infants | Phase 2 |
| Undisclosed LBP | Prevention of Necrotizing Enterocolitis (NEC) | Preclinical |
| Drug | Indication | Phase |
|---|---|---|
| STMC-103H | Prevention of Atopic Dermatitis in high-risk infants | Phase 2 |
| Undisclosed LBP | Prevention of Necrotizing Enterocolitis (NEC) | Preclinical |